Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.60 |
| ▸ | CA12 | O43570 | 3/20 | 0.59 |
| ▸ | CA1 | P00915 | 3/20 | 0.59 |
| ▸ | CA2 | P00918 | 3/20 | 0.59 |
| ▸ | CA9 | Q16790 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.35 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MLYCD | O95822 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18737910 | 0.86 | MEN1 (0.64) | KMT2AMEN1PABPC1CA12CA1 | |
| SCHEMBL24230437 | 0.84 | CA12 (0.64) | KMT2AMEN1PABPC1CA12CA1 | |
| SCHEMBL16569258 | 0.84 | MEN1 (0.61) | KMT2AMEN1PABPC1CA12CA1 | |
| SCHEMBL21711170 | 0.84 | MEN1 (0.61) | KMT2AMEN1PABPC1CA12CA1 | |
| SCHEMBL5355079 | 0.83 | MEN1 (0.64) | KMT2AMEN1PABPC1CA12CA1 | |
| SCHEMBL15788844 | 0.83 | KMT2A (0.72) | KMT2AMEN1PABPC1CA12CA1 | |
| SCHEMBL24230197 | 0.82 | MEN1 (0.60) | KMT2AMEN1PABPC1CA12CA1 | |
| SCHEMBL23588594 | 0.82 | MEN1 (0.60) | KMT2AMEN1PABPC1CA12CA1 | |
| SCHEMBL19979296 | 0.82 | CA12 (0.62) | KMT2AMEN1PABPC1CA12CA1 | |
| SCHEMBL5359267 | 0.81 | CA12 (0.61) | KMT2AMEN1PABPC1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303577-A1 | TEMOZOLOMIDE ANALOGS AND METHODS OF USE | ST. JOHN'S CANCER INSTITUTE (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303577-A1 | TEMOZOLOMIDE ANALOGS AND METHODS OF USE | ST. JOHN'S CANCER INSTITUTE (US) | 2023-09-28 | — | — | US | disclosed |
| WO-2022026756-A1 | TEMOZOLOMIDE ANALOGS AND METHODS OF USE | ST. JOHN'S CANCER INSTITUTE (US) | 2022-02-03 | — | — | WO | disclosed |
| US-7173021-B2 | Synthesis of temozolomide esters as potent anticancer pro-drugs for topical and transdermal applications in treatments of cancers | TIANJIN NORTH PHARM SCI-TECH CO., LTD. (CN) | 2007-02-06 | — | — | US | disclosed |
| US-20060047117-A1 | Synthesis of temozolomide esters as potent anticancer pro-drugs for topical and transdermal applications in treatments of cancers | TIANJIN NORTH PHARM SCI-TECH CO., LTD. (CN) | 2006-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060047117-A1 | Synthesis of temozolomide esters as potent anticancer pro-drugs for topical and transdermal applications in treatments of cancers | TET1, SLC16A1, ADH1A | KMT2A 1472/4885MEN1 222/4885PABPC1 4434/4885 |
| US-20230303577-A1 | TEMOZOLOMIDE ANALOGS AND METHODS OF USE | MGMT, TOP2B, IDH3B | KMT2A 524/4885MEN1 882/4885PABPC1 2801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.